Literature DB >> 38084

The metabolism of DL-[14C]verapamil in man.

M Eichelbaum, M Ende, G Remberg, M Schomerus, H J Dengler.   

Abstract

The metabolism of DL-verapamil in man was studied after oral administration of an aqueous solution of DL-[14C]verapamil. Between 67 and 71% of the 14C administered was excreted in the urine within 5 days. Verapamil was extensively metabolized; only 3--4% of the dose was excreted in the urine as unchanged drug. Cleavage of the C--N--C bond by N-'dealkylation, preferentially at the C-atom belonging to the shorter side chain, was the main metabolic step. Verapamil and its N-dealkylated metabolites were further metabolized by O-demethylation. Inasmuch as approximately 10 times more of the metabolites formed from the tertiary amine verapamil are secondary amines than are primary amines, it would seem that N-dealkylation of this tertiary amine proceeds at a much higher rate than the N-dealkylation of the secondary amine metabolites to primary amine metabolites.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 38084

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  43 in total

1.  Pharmacokinetics and pharmacodynamics of verapamil following sublingual and oral administration to healthy volunteers.

Authors:  D N John; S Fort; M J Lewis; D K Luscombe
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

2.  MS(M), an efficient workflow for metabolite identification using hybrid linear ion trap Orbitrap mass spectrometer.

Authors:  Robert Cho; Yingying Huang; Jae C Schwartz; Yan Chen; Timothy J Carlson; Ji Ma
Journal:  J Am Soc Mass Spectrom       Date:  2012-02-14       Impact factor: 3.109

3.  Evaluation of potential pharmacodynamic and pharmacokinetic interactions between verapamil and propranolol in normal subjects.

Authors:  D L Murdoch; G D Thomson; G G Thompson; G D Murray; M J Brodie; G T McInnes
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

4.  The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris.

Authors:  J C McCourty; J H Silas; G T Tucker; M S Lennard
Journal:  Br J Clin Pharmacol       Date:  1988-03       Impact factor: 4.335

5.  Verapamil pharmacokinetics and apparent hepatic and renal blood flow.

Authors:  P A Meredith; H L Elliott; F Pasanisi; A W Kelman; D J Sumner; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1985-08       Impact factor: 4.335

6.  Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin.

Authors:  Dong-Hyun Choi; Joong-Hwa Chung; Jun-Shik Choi
Journal:  Eur J Clin Pharmacol       Date:  2009-12-12       Impact factor: 2.953

7.  Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis.

Authors:  A Somogyi; M Albrecht; G Kliems; K Schäfer; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1981-07       Impact factor: 4.335

8.  A panel of cytochrome P450 BM3 variants to produce drug metabolites and diversify lead compounds.

Authors:  Andrew M Sawayama; Michael M Y Chen; Palaniappan Kulanthaivel; Ming-Shang Kuo; Horst Hemmerle; Frances H Arnold
Journal:  Chemistry       Date:  2009-11-02       Impact factor: 5.236

9.  Single dose pharmacokinetics of fendiline in humans.

Authors:  W R Kukovetz; F Brunner; E Beubler; R Weyhenmeyer; R Lohaus; M Grob; D Mayer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982       Impact factor: 2.441

10.  Identification of P450 enzymes involved in metabolism of verapamil in humans.

Authors:  H K Kroemer; J C Gautier; P Beaune; C Henderson; C R Wolf; M Eichelbaum
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-09       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.